Predicting Pathological Complete Response Following Neoadjuvant Therapy in Patients With Breast Cancer: Development of Machine Learning-Based Prediction Models in a Retrospective Study.

Journal: JMIR cancer
Published Date:

Abstract

BACKGROUND: Breast cancer is the most prevalent form of cancer worldwide, with 2.3 million new diagnoses in 2022. Recent advancements in treatment have led to a shift in the use of chemotherapy-targeted immunotherapy from a postoperative adjuvant to a preoperative neoadjuvant approach in select cases, resulting in enhanced survival outcomes. A pathological complete response (pCR) is a critical prognostic marker, with higher pCR rates linked to improved overall and disease-free survival.

Authors

  • Chun-Chi Lai
    Bachelor Program in Interdisciplinary Studies, National Yunlin University of Science and Technology, 123 University Road, Section 3, Douliou, Yunlin, 64002, Taiwan.
  • Cheng-Yu Chen
    Department of Medical Imaging, Taipei Medical University Hospital, No.250, Wu-Hsing St, Taipei, 11031, Taiwan. sandy0932@gmail.com.
  • Tzu-Hao Chang
    International Center for Health Information Technology, Taipei Medical University, Taipei, Taiwan.